Printer Friendly

CYCLOTRON TO SPUR THERAGENICS' EXPANSION PROJECT

 CYCLOTRON TO SPUR THERAGENICS' EXPANSION PROJECT
 ATLANTA, June 15 /PRNewswire/ -- Theragenics Corporation


(NASDAQ: THRX), a cancer-therapy company based here, today said it had earmarked $3 million raised in a private placement earlier this month for the installation of a cyclotron at a new manufacturing facility in Buford, Ga. The cyclotron will produce palladium-103, a radioisotope used in the company's TheraSeed(R) radioactive implant for the outpatient treatment of prostate and other localized cancers.
 President and Chief Executive Officer John V. Herndon said the cyclotron will "increase capacity, while significantly improving long- term manufacturing flexibility and profitability, allowing Theragenics to meet rapidly expanding demand for TheraSeed." He said the cyclotron is scheduled to be delivered during the fourth quarter of 1992.
 Current production procedures for TheraSeed involve several outside production services available to Theragenics through a limited number of outside suppliers. The cyclotron is intended to eliminate the need to use these outside production sources and allow the company to manufacture, more cost effectively, larger quantities of its product with greater reliability and timeliness, thereby improving service to the nearly 100 oncology centers in the United States using TheraSeed.
 Herndon said that of the more than 130,000 new cases of prostate cancer to be diagnosed in the United States in 1992, some 70,000 will be suitable for TheraSeed treatment, representing a market opportunity in excess of $200 million for the year. He said TheraSeed is also applicable to and approved for other localized cancers, such as those found in the head and neck, the eye, lung, brain and the pancreas. Foreign markets, which have at least as much potential as the U.S. are currently being addressed, added the CEO.
 "We are confident of another record quarter in June," said Herndon, "and we anticipate further significant growth in revenues and earnings in succeeding quarters, as demand for our TheraSeed product continues to increase. We
 6/15/92
 /CONTACT: Bruce Smith, CFO of Theragenics Corporation, 404-381-8338, or Rick Eisenberg of Eisenberg Communications, 212-496-6828, for Theragenics/
 (THRX) CO: Theragenics Corporation ST: Georgia IN: MTC SU:


SB-TQ -- NY059 -- 0235 06/15/92 14:22 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 15, 1992
Words:353
Previous Article:BERGEN BRUNSWIG REPORTS THIRD QUARTER AND NINE MONTH RESULTS
Next Article:TELEGLOBE CANADA COMMISSIONS INTERNATIONAL COMMUNICATIONS LINK WITH SCIENTIFIC-ATLANTA'S DIGITAL ANALYSIS SYSTEM
Topics:


Related Articles
THERAGENICS RECORDS THIRD CONSECUTIVE PROFITABLE QUARTER; SUCCESS OF CANCER THERAPY PRODUCT BOOSTS REVENUE 120 PERCENT
THERAGENICS ANNOUNCES THIRD QUARTER RESULTS
The Law Firm of Abbey, Gardy & Squitieri, LLP Announces Pendency of Class Action Against Theragenics Corp.
Weiss & Yourman Announces Class Action Against Theragenics on Behalf of Theragenics Shareholders.
Spector & Roseman, P.C. Announces Class Action Lawsuit Filed Against Theragenics Corp. and Certain Officers and Directors on Behalf of All Purchasers...
/FROM PR NEWSWIRE PHILADELPHIA 800-523-4424/ TO BUSINESS EDITOR:.
/FROM PR NEWSWIRE PHILADELPHIA 800-523-4424/ TO BUSINESS EDITOR:.
Doe Signs Agreement for Oak Ridge Technology, Equipment to be Used in Prostate Cancer Treatment.
Theragenics Corporation(R) Appoints Bruce Smith as Acting Chief Financial Officer.
International Physician Networks dba International Urology Network and Theragenics Corporation Sign Exclusive Three-Year Strategic Alliance.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters